Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial-Reference-Cited by-同舟云学术

Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial

Published:2024-04 Issue:2 Volume:14 Page:
ISSN:2163-0402
Container-title:Neurology Clinical Practice
language:en
Short-container-title:Neur Clin Pract

Author:

Grill Joshua D.¹^ORCID,Raman Rema¹^ORCID,Ernstrom Karin¹^ORCID,Wang Shunran¹^ORCID,Donohue Michael C.¹^ORCID,Aisen Paul S.¹^ORCID,Karlawish Jason¹^ORCID,Henley David¹^ORCID,Romano Gary¹,Novak Gerald¹^ORCID,Brashear H. Robert¹,Sperling Reisa A.¹^ORCID

Affiliation:

1. Institute for Memory Impairments and Neurological Disorders (JDG), Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California Irvine, Irvine; Alzheimer's Therapeutic Research Institute (RR, KE, SW, MCD, PSA), University of Southern California, San Diego; University of Pennsylvania (JK), Philadelphia; Janssen Research & Development LLC (DH, GR, GN), Titusville, NJ; Indiana University School of Medicine (DH, HRB), Indianapolis; University of Virginia (HRB)...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/CPJ.0000000000200265

Reference45 articles.

1. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

2. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

3. Hoffman La Roche. A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE). U.S. National Library of Medicine. 2022. Accessed September 8, 2022. ClinicalTrials.gov.

4. Eli Lilly and Company. A Donanemab (LY3002813) Prevention Study in Participants with Alzheimer's Disease (TRAILBLAZER-ALZ 3). U.S. National Library of Medicine. 2021. Accessed September 8, 2022. ClinicalTrials.gov.

5. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psychosocial implications of learning amyloid PET results in an observational cohort;Alzheimer's & Dementia;2024-08-11

2. Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer’s Disease Trial;The Journal of Prevention of Alzheimer's Disease;2024